Following US pharmaceutical giant Pfizer’s failed attempt to acquire AstraZeneca, reports say Pfizer has inked a new joint venture deal to develop immunotherapy cancer drugs.
According to reports, Pfizer will team up with France-based Cellectis. The partnership involves Pfizer paying Cellectis $80 million upfront, as well as funding for ongoing research into the new treatment.
Among the other aspects of the deal, Pfizer will also acquire a 10 percent stake in the French company.
The joint venture was announced Wednesday and follows last month’s failure for Pfizer to convince AstraZeneca to merge. Pfizer raised its bid as high as $118 billion to purchase the UK firm.
Full content: Yahoo News
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
FTC Urged to Enforce Rarely Used Antitrust Law Against Retail Giants
Mar 28, 2024 by
CPI
UK’s Fingleton Bolsters Team with New Additions
Mar 28, 2024 by
CPI
Britain’s Competition Regulator Clears Aviva’s Acquisition of AIG Life UK
Mar 28, 2024 by
CPI
White House Implements New AI Safeguards to Protect Rights and Safety
Mar 28, 2024 by
CPI
Denver Court Sets August Date for Kroger-Albertsons Merger Showdown
Mar 28, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Real Estate & Antitrust
Mar 27, 2024 by
CPI
Systematic National Evidence of Steering by Real Estate Agents
Mar 27, 2024 by
CPI
Compliance Now! Actionable Antitrust Advice for the Residential Real Estate Industry
Mar 27, 2024 by
CPI
Real Estate Commissions: Some Insights from the Economics of Multi-Sided Platforms
Mar 27, 2024 by
CPI
New Ideas for Promoting Real Estate Brokerage Price Competition
Mar 27, 2024 by
CPI